Pentamidine (isethionate)

Pentamidine isethionate (MP-601205 isethionate) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine isethionate inhibits parasite Leishmania infantum with an IC50 of 2.5 μM. Pentamidine isethionate is a potent and selective protein tyrosine phosphatases (PTPases) and phosphatase of regenerating liver (PRL) inhibitor. Pentamidine isethionate has the potential for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment. Antitumor and antibacterial activities[1][2][3][4].

Product Specifications

CAS Number

[140-64-7]

Product Name Alternative

MP-601205 (isethionate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial; Fungal; Parasite; Phosphatase

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Pentamidine-isethionate.html

Concentration

10mM

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

N=C(C1=CC=C(OCCCCCOC2=CC=C(C(N)=N)C=C2)C=C1)N.OCCS(=O)(O)=O.OCCS(=O)(O)=O

Molecular Formula

C23H36N4O10S2

Molecular Weight

592.68

Precautions

H302, H315, H319, H335

References & Citations

[1]Sands M, et al. Pentamidine: a review. Rev Infect Dis. 1985 Sep-Oct;7 (5) :625-34.|[2]Pathak MK, et al. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002 Dec;1 (14) :1255-64.|[3]Nguewa, P.A., et al., Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers, 2005. 2 (10) : p. 1387-400.|[4]David C. Bean, et al. Pentamidine: a drug to consider re-purposing in the targeted treatment of multi-drug resistant bacterial infections? J Lab Precis Med 2017;2:49.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

Leishmania; Trypanosoma

Citation 01

Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Biochem Biophys Res Commun. 2019 Sep 17;517 (2) :221-226.|BMC Womens Health. 2022 Nov 24;22 (1) :470.|Drug Des Devel Ther. 2021 Jul 1;15:2857-2868.|Immunity. 2023 Feb 14;56 (2) :272-288.e7.|Int J Mol Sci. 2023 Sep 7;24 (18) :13812.|Microbiol Spectr. 2023 Jun 15;11 (3) :e0313822.|Molecules. 2020 Apr 23;25 (8) :1980.